It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

ZIEXTENZO can help protect you from the risk of infection

Your doctor prescribed ZIEXTENZO to help reduce the risk of infection during chemotherapy. ZIEXTENZO is a man-made form of granulocyte colony-stimulating factor (G-CSF) called pegfilgrastim. G-CSF is a natural substance produced by the body. The purpose of G-CSF is to stimulate the growth of neutrophils, a type of white blood cell important in the body's fight against infection.

Ziextenzo Logo

ZIEXTENZO is a biosimilar of Neulasta®

ZIEXTENZO vs Neulasta. Works the same way. Offers the same protection. Has the same side effects.

Neulasta® and ZIEXTENZO are biologics, which are complex medications developed by cutting-edge technology. Biologics may consist of sugars, proteins, or nucleic acids, or may be living entities such as cells and tissues.

What are biosimilars?

Biosimilars are engineered to match the structure of biologic efficacy and safety profiles. 54% of all FDA – Approved biosimilars are oncology specific.

*The alternative biologic tbo-filgrastim (Granix®) was treated as a biosimilar for the purposes of the analysis.
Granix is a registered trademark of Cephalon, Inc.
Neulasta is a registered trademark of Amgen Inc.